These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 20018309)

  • 61. In Reply to Bhattacharyya et al.
    Cho E; Mostaghel EA; Russell KJ; Liao JJ; Montgomery B
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):719-20. PubMed ID: 26461011
    [No Abstract]   [Full Text] [Related]  

  • 62. Editorial comment.
    Macaluso JN
    Urology; 2014 Feb; 83(2):384. PubMed ID: 24315303
    [No Abstract]   [Full Text] [Related]  

  • 63. External Beam Radiation Therapy and Abiraterone in Men With Localized Prostate Cancer: Safety and Effect on Tissue Androgens. In Regard to Cho et al.
    Bhattacharyya T; Purushothaman K; Puthiyottil SS; Muttath G
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):719. PubMed ID: 26461012
    [No Abstract]   [Full Text] [Related]  

  • 64. Re: Nicolas Mottet, Joaquim Bellmunt, Erik Briers, et al. EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. European Association of Urology; 2017. http://uroweb.org/guideline/prostate-cancer: How to Assess the Efficacy of Medical Castration.
    Morote J; Comas I; Planas J
    Eur Urol; 2018 May; 73(5):e134-e135. PubMed ID: 29452710
    [No Abstract]   [Full Text] [Related]  

  • 65. Minimizing the risk of sarcopenic obesity during androgen deprivation therapy-promising results for men treated with GnRH antagonists.
    Csizmadi I
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):589-590. PubMed ID: 33820952
    [No Abstract]   [Full Text] [Related]  

  • 66. In Regard to Bauman et al.
    Kishan AU; Steinberg ML; Kupelian PA; King CR
    Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1162-3. PubMed ID: 26581152
    [No Abstract]   [Full Text] [Related]  

  • 67. In Reply to Kishan et al.
    Bauman G; Rodrigues G; Chen J; Loblaw A
    Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1163. PubMed ID: 26581153
    [No Abstract]   [Full Text] [Related]  

  • 68. Editorial comment from Dr Hsiao to Prognostic impact of young age on stage IV prostate cancer treated with primary androgen deprivation therapy.
    Hsiao W
    Int J Urol; 2014 Jun; 21(6):584-5. PubMed ID: 24446691
    [No Abstract]   [Full Text] [Related]  

  • 69. Editorial comment from Dr Shiota to Prognostic impact of young age on stage IV prostate cancer treated with primary androgen deprivation therapy.
    Shiota M
    Int J Urol; 2014 Jun; 21(6):583-4. PubMed ID: 24404863
    [No Abstract]   [Full Text] [Related]  

  • 70. Editorial comment.
    Derweesh IH
    J Urol; 2011 Aug; 186(2):480-1; author reply 481. PubMed ID: 21705032
    [No Abstract]   [Full Text] [Related]  

  • 71. New evidence in neoplastic and cardiovascular medicine.
    Conti AA; Dilaghi B; Modesti PA; Nozzoli C
    Intern Emerg Med; 2009 Oct; 4(5):429-31. PubMed ID: 19707846
    [No Abstract]   [Full Text] [Related]  

  • 72. In regard to Sherertz et al., IJROBP 2001; 51:1241-1245.
    Pollack A; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):512; author reply 512. PubMed ID: 12023157
    [No Abstract]   [Full Text] [Related]  

  • 73. Editorial Comment to Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer.
    Kawahara T
    Int J Urol; 2020 Oct; 27(10):837-838. PubMed ID: 32770604
    [No Abstract]   [Full Text] [Related]  

  • 74. Editorial Comment to Relationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer.
    Gandaglia G; Montorsi F; Briganti A
    Int J Urol; 2016 Apr; 23(4):312. PubMed ID: 26790633
    [No Abstract]   [Full Text] [Related]  

  • 75. Re: Editorial comment.
    Goldenberg SL; Gleave ME; Bruchovsky N; Rennie P
    J Urol; 1997 Jun; 157(6):2267. PubMed ID: 9146650
    [No Abstract]   [Full Text] [Related]  

  • 76. Editorial comment.
    Rais-Bahrami S; Moreira DM
    J Urol; 2012 Dec; 188(6):2188; discussion 2189. PubMed ID: 23083847
    [No Abstract]   [Full Text] [Related]  

  • 77. Editorial Comment.
    Kamada S
    J Urol; 2018 Mar; 199(3):740. PubMed ID: 29154762
    [No Abstract]   [Full Text] [Related]  

  • 78. Editorial Comment to Treatment-induced changes in levels of brain natriuretic peptide in prostate cancer patients receiving gonadotropin-releasing hormone antagonists or agonists.
    Takahashi S
    Int J Urol; 2020 Apr; 27(4):356. PubMed ID: 32128915
    [No Abstract]   [Full Text] [Related]  

  • 79. Re: Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists.
    Albertsen PC
    Eur J Cancer; 2017 Dec; 87():203. PubMed ID: 28947070
    [No Abstract]   [Full Text] [Related]  

  • 80. Response to letter - Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists.
    Scailteux LM
    Eur J Cancer; 2017 Dec; 87():204. PubMed ID: 28756060
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.